医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

MEDINET and MaxCyte announce publication of joint collaboration supporting delivery of enhanced potency immunotherapy technology for treatment of cancer

2013年03月27日 PM09:25
このエントリーをはてなブックマークに追加


 

GAITHERSBURG, Md. & SHIN-YOKOHAMA, Japan

MEDINET Co. Ltd. (TSE: #2370) and MaxCyte, Inc. announce the publication of the results of their scientific collaboration demonstrating that the use of MaxCyte’s cell loading technology results in 5 – 20 fold enhancement in potency of dendritic cell vaccines. The manuscript entitled ‘Clinical scale electroloading of mature dendritic cells with melanoma whole tumor cell lysate is superior to conventional lysate co-incubation in triggering robust in vitro expansion of functional antigen-specific CTL’ was published in the journal International Immunopharmacology and can be accessed online at http://dx.doi.org/10.1016/j.intimp.2013.01.009.

“This publication provides clear scientific evidence of MEDINET’s leadership position in bringing advanced immunotherapies to cancer patients in Japan,” says Mr. Yoshiji Kimura, MEDINET’s Chief Executive Officer, “and will enhance our ability to provide the highest quality cancer immuno-cell therapies through our expanding network of Contracted Medical Institutions.”

“MEDINET is the leader of the world in cell-based therapies, with world-class expertise in immunotherapeutics,” says Douglas A. Doerfler, President and Chief Executive Officer of MaxCyte, “and we look forward to continuing to build on our strong and long-standing partnership.”

MEDINET has previously entered into an exclusive license agreement to use MaxCyte’s proprietary cell loading system to support clinical studies and commercialize treatment of cancer patients; and subsequently expanded the license to additional Asia-Pacific countries. MEDINET is currently marketing its cancer immunotherapy service in Japan and the largest provider in the country.

About MEDINET

MEDINET is a world leading company in cell therapy, supporting medical service providers in Japan. Through its service, MEDINET provides medical institutions with advanced technologies and knowhow in: cell processing and culturing, quality control, and facility management with respect to the immuno-cell therapy. MEDINET has extensive experience in autologous cell processing; with nearly 15,000 cancer patients treated in actual clinical practice through more than 124,000 cell therapy manufacturing processes. MEDINET continues to invest in R&D to improve cell processing technologies in an effort to increase efficacy in collaborative clinical studies with university hospitals and medical institutions. MEDINET went public in October, 2003 on the MOTHERS, Tokyo Stock Exchange.

For more information, visit http://www.medinet-inc.co.jp/english/.

About MaxCyte

MaxCyte is the leading provider of clinical and commercial high throughput cell modification technologies to global leaders in life sciences industry. MaxCyte’s transfection technology platform enables the discovery, development, manufacturing and delivery of innovative and important therapeutic products for a wide range of diseases. By providing unparalleled consistency, scalability, and loading efficiency while avoiding the inherent drawbacks of alternative methods. MaxCyte markets the MaxCyte® STX™ Scalable Transfection System to biopharmaceutical companies for cell-based drug screening and small molecule drug discovery.

For more information, visit http://www.maxcyte.com.

This is an abridged translation of abstract of MEDINET’s press. MEDINET made its best efforts to translate with accuracy but it does not mean that the translation is the same description as the original. This press release was created for the purpose of providing information that will help investors make informed decisions. It was not created to solicit investors to buy or sell MEDINET’s stock. The final decision and responsibility for investments rests solely with the user of this release and its content. Furthermore, opinions, forecasts and other content found in this release are based on assumptions and beliefs of MEDINET at the time of preparation. While every effort is made to ensure the accuracy of information described in this release, MEDINET assumes no responsibility, whatsoever, for any losses resulting from the use of this release or its description.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130327005148/en/

CONTACT

MEDINET Co., Ltd.
Yoshiji Kimura
Representative
Director of the Board
President and Chief Executive Officer
Phone:
+81 (0)45 478 0041
Fax: +81 (0)45 478 0043
ir@medinet-inc.co.jp
www.medinet-inc.co.jp/english
or
MaxCyte,
Inc.

Douglas A. Doerfler
President and Chief Executive
Officer
Phone: +1 301 944 1700
Fax: +1 301 944 1703
info@maxcyte.com
www.maxcyte.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作